BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12077549)

  • 21. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
    Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
    Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide-associated thrombosis in the treatment of HIV-associated severe aphthous disease: a case report and review of the literature.
    Hodowanec AC; Han A; Barker DE; Rubinstein PG; Max B
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):345-7. PubMed ID: 22930795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
    Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
    Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
    South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalidomide-induced fulminant hepatic failure.
    Hamadani M; Benson DM; Copelan EA
    Mayo Clin Proc; 2007 May; 82(5):638. PubMed ID: 17493431
    [No Abstract]   [Full Text] [Related]  

  • 26. Thalidomide therapy and polyneuropathy in myeloma patients.
    Laaksonen S; Remes K; Koskela K; Voipio-Pulkki LM; Falck B
    Electromyogr Clin Neurophysiol; 2005 Mar; 45(2):75-86. PubMed ID: 15861857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythroderma due to thalidomide: report of two cases.
    Bielsa I; Teixidó J; Ribera M; Ferrándiz C
    Dermatology; 1994; 189(2):179-81. PubMed ID: 8075450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Renaissance of thalidomide].
    Waelput F; Feremans W; Heenen M; Sternon J
    Rev Med Brux; 2002 Dec; 23(6):504-11. PubMed ID: 12584947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should we screen patients for inherited thrombophilia before starting thalidomide?
    Otrock ZK; Mahfouz RA; El-Hajj II; Harb MI; Sawaya RA
    Am J Clin Oncol; 2006 Feb; 29(1):100-1. PubMed ID: 16462512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in the treatment of multiple myeloma.
    Kumar S
    Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thalidomide induced peripheral neuropathy in multiple myeloma patients].
    Banach M; Jurczyszyn A; Skotnicki A
    Przegl Lek; 2015; 72(11):629-35. PubMed ID: 27012121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
    Borges Lde G; Frõehlich PE
    Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous adverse reactions to lenalidomide.
    Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
    Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of thalidomide in the treatment of cancer.
    Rajkumar SV
    Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recalcitrant pyoderma gangrenosum treated with thalidomide.
    Federman GL; Federman DG
    Mayo Clin Proc; 2000 Aug; 75(8):842-4. PubMed ID: 10943240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
    Aboulafia DM
    AIDS Read; 2003 Aug; 13(8):383-9. PubMed ID: 14524324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.
    Younis TH; Alam A; Paplham P; Spangenthal E; McCarthy P
    Br J Haematol; 2003 Apr; 121(1):191-2. PubMed ID: 12670354
    [No Abstract]   [Full Text] [Related]  

  • 40. [Desirable and undesirable effects of thalidomide in patients with multiple myeloma].
    Foldyna D; Kamelander J; Krejcí M; Hájek R
    Vnitr Lek; 2003 Nov; 49(11):859-68. PubMed ID: 14689682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.